Headlines about Zoetis (NYSE:ZTS) have trended somewhat positive on Friday, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zoetis earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.9520807768348 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Analyst mean rating stands at 1.90while Zoetis Inc. (ZTS) closes Yesterday with change of -0.30% (nasdaqfortune.com)
- Investor Watch for Zoetis Inc. (NYSE:ZTS): 20 day Chaikin Seen at 0.27900258 (mtlnewsjournal.com)
- Global Veterinary Medicine Market Study 2018- Zoetis Inc. , Merck Animal Health, Merial Inc., Boehringer Ingelheim (nwctrail.com)
- Zoetis Inc (ZTS) Expected to Post Quarterly Sales of $1.39 Billion (americanbankingnews.com)
- Analysts Anticipate Zoetis Inc (ZTS) to Post $0.71 EPS (americanbankingnews.com)
A number of research firms have recently issued reports on ZTS. Hilliard Lyons downgraded Zoetis to a “neutral” rating in a research note on Thursday, April 19th. They noted that the move was a valuation call. Morgan Stanley downgraded Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 target price on the stock. in a research report on Monday, March 19th. They noted that the move was a valuation call. BMO Capital Markets reiterated a “hold” rating and set a $80.00 target price on shares of Zoetis in a research report on Wednesday, May 16th. Citigroup reiterated a “buy” rating and set a $98.00 target price (up from $85.00) on shares of Zoetis in a research report on Thursday, April 19th. Finally, Cantor Fitzgerald set a $90.00 target price on Zoetis and gave the company a “buy” rating in a research report on Tuesday, May 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $84.73.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.35 billion. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The business’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period last year, the firm earned $0.53 earnings per share. sell-side analysts anticipate that Zoetis will post 3.06 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a $0.126 dividend. The ex-dividend date of this dividend is Thursday, July 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.58%. Zoetis’s dividend payout ratio (DPR) is 20.83%.
In other news, insider Kristin C. Peck sold 4,877 shares of Zoetis stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $83.46, for a total value of $407,034.42. Following the sale, the insider now directly owns 42,652 shares of the company’s stock, valued at $3,559,735.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.35% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.